MANATEE-T1D: Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 Diabetes
Child to Adult
Youth ages 12-21 with diagnosis of Type 1 Diabetes on an hybrid closed loop artificial pancreas system OR on multiple daily injections + continuous glucose monitor for at least 6 months
T1D by ADA criteria On an HCL AP system OR MDI+CGM for > 6 months Age 12-21 years HbA1c < 11% No recent diabetic ketoacidosis or hyperosmolar hyperglycemia Tanner stage 2 or greater Weight > 54 kg and BMI > 5th percentile Not pregnant or breastfeeding No use of anti-diabetic agents except insulin, ACE inhibitors, angiotensin receptor blockers (ARB’s), diuretics, daily NSAIDs or aspirin, sulfonamides, procaine, thiazolesulfone or probenecid No seafood or iodine allergy
Treatment
Barbara Davis Center
Childrens Hospital Colorado
Kalie Tommerdahl, MD
Protocol Number: 21-3483
More information available at ClinicalTrials.gov: NCT05065372
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers